New animal model offers insights into pancreatic disease and diabetes
Cystic fibrosis (CF) is a life-threatening genetic disease affecting multiple organ systems, with pancreatic dysfunction ...
Armed robbery in Revesby1d
Pancreatic Disease, Diabetes: New Insights Unveiled
Cystic fibrosis (CF) is a life-threatening genetic disease affecting multiple organ systems, with pancreatic dysfunction representing a critical and ...
AFP3d
Vertex Announces US FDA Approval of ALYFTREKâ„¢, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to ...
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...
Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani Hosts 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor ...
lifesciencesweden.se9d
FDA approves new cystic fibrosis therapy
A new treatment for cystic fibrosis has been approved by the U.S. Food and Drug Administration (FDA).
Lupin receives US FDA tentative approval for Ivacaftor Oral Granules
These granules, available in 25 mg, 50 mg, and 75 mg per unit dose packets, are a generic equivalent of Kalydeco Oral ...
Pharmabiz10d
Arcturus Therapeutics initiates patient dosing in phase 2 multiple ascending dose studies for CF and OTC deficiency
Arcturus Therapeutics initiates patient dosing in phase 2 multiple ascending dose studies for CF and OTC deficiency: San Diego Wednesday, January 8, 2025, 13:00 Hrs [IST] Arcturus ...
Hosted on MSN13d
FDA Wraps Up 2024 Handing Out Several Notable Regulatory Decisions
Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory ...